Canada and European Union agreement makes good progress
This article was originally published in Clinica
Progress made in discussions on the mutual recognition agreement between Canada and the European Union has been such that the 18-month confidence-building phase can begin, it was agreed at a meeting in Brussels last month. The first issue to be addressed in this transitional phase will be the premarket review of scientific/technical submissions (design dossier reviews in the EU).
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.